HCM HUTCHMED (China) Limited
$14.27▼ -0.63%
Healthcare
Other
Pre-market
$14.03▼ -1.68%
Oct 27, 7:02 AM ET
Volume 19.1K
Avg Volume (10D) 41.1K
Key Metrics & Fundamentals
Market Cap
$2.48B
P/E Ratio
142.7
Div Yield
0.00%
52W Range
9.77 - 16.33
% vs 50 MA
5.10%
% vs 200 MA
7.66%
RSI-14
54.1
MACD Histogram
-0.0100
Beta (1Y vs SPY)
0.76
Gross Rev
–
Gross Profit
–
EBITDA
–
COGS
–
Operating Exp
–
Operating Income
–
EBIT
–
Pretax Income
–
Net Income
–
Price & Volume History
Loading chart…
Recent News
Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer
GlobeNewswire · Oct 26, 2026 8:00 PM ET
HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026
GlobeNewswire · Oct 26, 2026 4:30 AM ET
HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine
GlobeNewswire · Oct 25, 2026 8:00 PM ET
What HUTCHMED (China) (AIM:HCM)'s GSK Licensing Deal Means For Shareholders
Simply Wall St. · Oct 25, 2026 3:12 AM ET
3 British Healthcare Stocks To Own In October 2026
Simply Wall St. · Oct 23, 2026 8:19 PM ET
HUTCHMED (China) (AIM:HCM) Closes GSK Deal, Is The Stock Still 38% Undervalued?
Simply Wall St. · Oct 22, 2026 8:19 PM ET
HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China
GlobeNewswire · Oct 20, 2026 8:00 PM ET
HUTCHMED (AIM:HCM) Stock Looks Expensive Relative To Current Earnings
Simply Wall St. · Oct 18, 2026 12:17 AM ET
3 British Healthcare Stocks To Own In October 2026
Simply Wall St. · Oct 16, 2026 7:12 PM ET
How Investors May Respond To HUTCHMED (China) (AIM:HCM) US NDA For ORPATHYS–TAGRISSO Lung Cancer Combo
Simply Wall St. · Oct 12, 2026 11:16 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.